Press Releases
iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice
Strategic commercial agreement in development will leverage Radiology Partners’ clinical expertise, ability to scale and leadership position to drive nationwide adoption of iCAD’s Breast AI Suite NASHUA, N.H. – November 10, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,…
iCAD Reports Financial Results for Third Quarter Ended September 30, 2022
Company implements corporate strategic realignment Partnership-based recurring revenue model anticipated to drive future growth Cost structure reduction to decrease expenses by over $3 million annually Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – November 10, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical…
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at…
iCAD and Solis Mammography Ink Deal to Collaborate on Use of AI to Evaluate Risk of Cardiovascular Disease
Multi-year strategic research and commercial collaboration agreement aims to significantly impact preventative care and underscores Company’s commitment to women’s health NASHUA, N.H. – October 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a new development and…
iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022
NASHUA, N.H., September 7, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the Lake Street Capital Markets, 6th Annual Best Ideas Growth (BIG6) Conference, taking place Wednesday, September 14, 2022 in New York…
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
Flexible subscription model accelerates deployment of iCAD’s Breast AI Suite, the only complete solution designed to comprehensively address today’s top imaging challenges NASHUA, N.H. – August 29, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that a…
iCAD Reports Financial Results For Second Quarter 2022
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – August 10, 2022 – iCAD, Inc….
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
NASHUA, N.H. – July, 27 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM…
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population NASHUA, N.H. – July 13, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today…
ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series
Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health Solutions NASHUA, N.H. – June 29, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that leading radiologists will highlight clinical…